Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable outcomes regardless of whether they underwent percutaneous coronary intervention (PCI) before TAVR, according to findings from the PRO-TAVI study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). TAVR is a minimally invasive procedure in which a new … Read more
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure at one year compared with patients who did not take the drug, according to a study presented at the American College of Cardiology’s Annual Scientific … Read more
TOPLINE: In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year incidence of bioprosthetic valve dysfunction than surgery. Valve dysfunction was also associated with an increased risk for death and hospitalization, regardless of replacement therapy. METHODOLOGY: Researchers conducted … Read more
TOPLINE: Compared with sevoflurane, a combination of remimazolam and flumazenil significantly reduces extubation time and use of ephedrine, while maintaining similar hemodynamic stability, in patients undergoing transcatheter aortic valve implantation (TAVI). METHODOLOGY: Researchers in Japan conducted a prospective, open-label, single-center clinical trial between June 2022 and August 2023 to compare emergence times with sevoflurane or … Read more